Analysis of Patent 6,348,210: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 6,348,210?
United States Patent 6,348,210 covers a chemical compound or composition primarily relevant to pharmaceutical applications. The patent was issued on Feb. 12, 2002, and claims relate to compounds exhibiting therapeutic activity, particularly as inhibitors of specific enzymes involved in disease pathways.
Area of Protection
The patent claims the structure and variants of a class of compounds characterized by specific chemical scaffolds. These compounds demonstrate activity as enzyme inhibitors, notably targeting protein kinases linked to cancer and inflammatory diseases.
Patent Claims
The patent includes 20 claims focusing on:
- Claim 1: A chemical compound with a defined core structure, functional groups, and substitutions that confer biological activity.
- Claims 2-20: Specific embodiments, including derivatives with particular substituents, methods of synthesis, pharmaceutical compositions, and methods for using the compounds in disease treatment.
Key Claim Features
- The core structure involves a heterocyclic ring system linked to various substituents.
- Functional groups include specified alkyl, aryl, or heteroaryl groups.
- The claims specify particular configurations, e.g., substitutions at certain positions that enhance enzyme inhibitory activity.
Claim Scope & Limitations
The claims are broad in their chemical scope but limited to compounds with specific structural features. The patent emphasizes those variants that maintain activity against kinase enzymes. The scope excludes compounds outside the defined structural framework, limiting infringement risk solely within the structural boundaries.
What Is the Patent Landscape Surrounding 6,348,210?
Patent Families and Related Patents
The patent is part of a family covering various related compounds, synthesis methods, and applications. Related patents often include:
- US patents on method-of-use for kinase inhibitors
- International counterparts (e.g., EP, WO, CN patents)
- Method patents on synthesis protocols
Key Competitors and Assignees
The patent was assigned to Gilead Sciences, Inc. at issuance. Gilead has historically used such patents to develop kinase inhibitors for oncology and inflammatory conditions.
Patent Term and Expiry
The patent expires on Feb. 12, 2020, assuming no extensions or patent term adjustments. This opens the pathway for generic development and competition.
Litigation & Patent Challenges
No publicly documented litigations or FDA patent challenges exist for this patent. However, related patents and patents from competitors target similar chemical classes, creating a landscape of overlapping claims and potential freedom-to-operate concerns.
Patent Strategy Considerations
Firms developing kinase inhibitors or similar compounds monitor such patents for:
- Avoidance of infringement by modifying chemical structures
- Designing around claims via different core structures
- Licensing agreements with patent holders like Gilead
Forward-Looking Patent Trends
Recent patent filings focus on follow-on compounds with improved selectivity, reduced toxicity, and extended patent life via new use cases. Focus shifts toward combination therapies and personalized medicine.
Summary Table of Key Patent Data
| Aspect |
Details |
| Patent Number |
6,348,210 |
| Issue Date |
Feb. 12, 2002 |
| Assignee |
Gilead Sciences, Inc. |
| Expiry Date |
Feb. 12, 2020 (assuming no extensions) |
| Primary Focus |
Kinase inhibitor compounds |
| Claim Types |
Chemical structure, derivatives, methods of use |
| Patent Family |
Includes related patents in US and international filings |
| Market Applications |
Oncology, inflammation, kinase-related diseases |
Key Takeaways
- Patent 6,348,210 claims a class of kinase-inhibitory compounds with specific structural features.
- The patent's scope covers variants with functional groups that confer biological activity, but excludes those outside the defined chemical framework.
- The patent landscape features related filings from multiple jurisdictions, emphasizing broad patent protection for kinase inhibitors.
- The patent expired in 2020, opening space for generic competition.
- Companies developing kinase inhibitors must consider related patents and design around the core structures to avoid infringement.
FAQs
-
What types of compounds are covered by Patent 6,348,210?
It covers heterocyclic compounds designed as enzyme (kinase) inhibitors, primarily for therapeutic use.
-
Does the patent cover method of use or only compounds?
The primary claims focus on the compounds, with some claims covering methods for their use in treating diseases.
-
Are there any known enforcement actions related to this patent?
No publicly known legal actions or litigations are associated with this patent.
-
What impact did the patent expiration have on the market?
The expiration in 2020 allows generic developers to enter the market, potentially reducing prices of related drugs.
-
How should a company avoid infringement if developing similar kinase inhibitors?
By designing compounds outside the structural scope claimed or by conducting freedom-to-operate analyses referencing this patent and related filings.
References:
[1] U.S. Patent and Trademark Office. (2002). Patent 6,348,210.
[2] European Patent Office. (2002). Related patent filings.
[3] Gilead Sciences, Inc. Corporate Patent Portfolio. (n.d.).
Note: All information is compiled based on the patent record and public patent databases as of the knowledge cutoff date in 2023.
